300181.SZ
Zhejiang Jolly Pharmaceutical Co., Ltd.
SZSE · Healthcare · C 制造业 · CN
CNY 13.98
−1.20%Aug 27, 2026, 08:46 UTC
Zhejiang Jolly Pharmaceutical announced a cash dividend of 3.5 yuan per 10 shares (tax inclusive) for the 2026 first half, with no capital reserve conversion to share capital.
Source:Aug 27, 2026, 08:46 UTC
Zhejiang Jolly Pharmaceutical disclosed its 2026 first-half results: revenue of 1.764 billion yuan, up 10.30% year-on-year; net profit attributable to shareholders of 375 million yuan, up 0.38% year-on-year; non-recurring-adjusted net profit of 374 million yuan, up 0.53% year-on-year.
Source:Aug 12, 2026, 08:42 UTC
Zhejiang Zuoli Pharmaceutical received approval from China's National Medical Products Administration to conduct clinical trials for its marketed product Linglianhua Granules for a new indication, perimenopausal syndrome with anxiety and heart-kidney non-communication syndrome.
Source:Jul 9, 2026, 08:41 UTC
Zhejiang Jolly Pharmaceutical and its subsidiary Qinghai Zhufeng Dongchongxiacao Pharmaceutical have 4 products included in the 2026 National Essential Drug List of China, effective September 1, 2026.
Source: